» Articles » PMID: 816458

Tissue Disposition of 3H-actinomycin D (NSC-3053) in the Rat, Monkey, and Dog

Overview
Specialties Oncology
Pharmacology
Date 1975 Nov 1
PMID 816458
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue concentration of 3H-actinomycin D have been determined in the rat, monkey, and dog after an iv dose of 0.6 mg/m2 body surface area. The drug-tissue half-life was determined for various tissues of the rat, monkey, and dog. A mean drug-tissue half-life of 47 hours was calculated for the tissues of the dog. Exceptions were the testis and brain. Significant concentrations of 3H-actinomycin D failed to accumulate in the brain. Although testis drug concentrations were lower than most other tissues evaluated, the drug-tissue half-life was significantly greater than that of other tissues. In all species studied 3H-actinomycin D was rapidly depleted from serum after iv dosage, with concomitant accumulation of drug in the tissues. 3H-actinomycin D was excreted via the biliary and urinary routes in all species studied. No metabolites of 3H-actinomycin D were detected in the bile or urine of the rat, monkey, or dog with the methods employed. When expressed on a body weight basis, body surface area doses were more than threefold greater in the rat than in the dog. However, the average ratio of concentration X time values (rat C X T/dog C X T) for 11 different tissues of the rat and dog was only 1.3. The results strongly suggest that an equivalent dose of actinomycin D, with dosage based on a body surface area basis, results in nearly equal tissue-drug exposure for most tissues in various mammalian species.

Citing Articles

Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.

Walsh C, Bonner J, Johnson T, Neuhoff S, Ghazaly E, Gribben J Br J Clin Pharmacol. 2016; 81(5):989-98.

PMID: 26727248 PMC: 4834588. DOI: 10.1111/bcp.12878.


Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Hill C, Jamieson D, Thomas H, Brown C, Boddy A, Veal G Biochem Pharmacol. 2012; 85(1):29-37.

PMID: 23063411 PMC: 3545186. DOI: 10.1016/j.bcp.2012.10.004.


Actinomycin D in the treatment of advanced breast cancer.

Grimm R, Muss H, White D, Richards 2nd F, Cooper M, Stuart J Cancer Chemother Pharmacol. 1980; 4(3):195-7.

PMID: 7397943 DOI: 10.1007/BF00254018.